PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Melatonin - Parkinson's disease
PAD Profile : Melatonin - Parkinson's disease Important
Keywords :
RBD, rapid eye movement disorder, PD, REM
Brand Names Include :
Circadin
Important Information :
Rapid eye movement disorder.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
Additional Documents
Type
Document
Review Date
Letter template (to patient)
Committee Recommendations
Date
Committee Name
Narrative
01 June 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Clonazepam or melatonin (generic 2mg MR tablets) may be considered to treat rapid eye movement sleep behaviour disorder (RBD) in people with Parkinson's Disease and sleep disturbance (unlicensed use).
A medicines review should first be undertaken to address any possible pharmacological causes.
Clonazepam or melatonin for this condition should only be initiated on request from a Parkinson's specialist
Associated BNF Codes
04. Central Nervous System
04.01.01. Hypnotics